Navigation Links
Researchers find no difference in drugs for macular degeneration
Date:9/30/2010

(Boston) Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is believed to be the first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to ranibizuamab. Last October, these same researchers published early, six month outcomes of the same study, which also failed to show a difference in efficacy between these two drugs for treating AMD.

AMD is the leading cause of blindness over the age of 50 in developed Western countries. It presents in two forms, exudative (wet) or nonexudative (dry). Wet AMD is often more visually devastating with a higher risk of blindness. The gold standard of treatment for wet AMD is ranibizumab (Lucentis, Genentech Inc.), which was FDA approved as an eye injection in 2006. Bevacizumab (Avastin, Genentech Inc.) was FDA approved for the treatment of colorectal cancer in 2004, but has also been used worldwide in an off-label fashion as an eye injection for the treatment of wet AMD. Lucenitis costs approximately $2000.00 per injection, while Avastin costs approximately $50.00 per injection. While both drugs have shown independently to be effective in treating wet AMD, it was uncertain if both drugs were equally efficacious or if either one was better.

In this study, patients were enrolled by a 2:1 ratio to receive either the Avastin or Lucentis. Patients were given eye injections of Avastin or Lucentis every month for the first three months, followed by monthly examination and testing. They received further injections on an as needed basis for one year.

Fifteen patients received Avastin and seven patients received Lucentis. There was no significant difference in visual acuity and anatomic outcomes between the two groups. Both groups had an average improvement in vision of 1.5 lines on the vision testing chart, and only one patient (who was in the Lucentis group) lost a significant amount of vision (three lines or more). In addition, patients in the Avastin group underwent an average of eight injections over one year, while patients in the Lucentis group underwent an average of four injections.

"With the exception that total injections given to subjects over one year were significantly different between the two treatment arms, visual and anatomic outcomes at one year failed to show a significant difference between both groups," said lead author and Principal Investigator Manju Subramanian, MD, an assistant professor in Ophthalmology at BUSM. According to the authors, further studies with larger sample sizes are warranted.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers advance biosynthesis of potent anti-cancer drug Taxol
2. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
3. Researchers at the University of Granada associate trigger points with shoulder injury
4. Researchers to study effects of Mass. health reform
5. IU researchers: Chemotherapy alters brain tissue in breast cancer patients
6. Researchers use CT to predict heart disease
7. VCU study: Researchers discover a drug combination that shrinks tumors in vivo
8. Sugary sports drinks mistakenly associated with being healthy, say UTHealth researchers
9. Researchers create first molecule blocks key component of cancer genes on-off switch
10. Researchers create first molecule-blocks key component of cancer genes on-off switch
11. Team of researchers finds possible new genetic risk for Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... , ... May 29, 2017 , ... ... a new training program for Recovery Coaches who are seeking opportunities to provide ... court systems, treatment centers, and others. Recovery Coaching and Professionalism© was created in ...
(Date:5/29/2017)... ... May 29, 2017 , ... ... in Springfield, Illinois, is the new president of the Board of Directors for ... for radiology practice administrators. He succeeds outgoing Board President Jim Hamilton, MHA, CMM, ...
(Date:5/28/2017)... ... ... Starting in May, patients at The Bay Clinic of Chiropractic ... , Nerve-Express, originally designed for the Navy in the 1980s, measures the change in ... nervous system (ANS). The ANS controls all the critical unconscious functions of the ...
(Date:5/28/2017)... ... May 28, 2017 , ... Florida ... to announce that Sheldon K. Cho, MD, has joined its Winter Haven practice. ... that concentrates on minimally invasive techniques to treat and manage many types of ...
(Date:5/27/2017)... ... ... dentist? You should go twice per year for checkups, but if you want to keep ... some dental tips to help out: , 1. Brushing Teeth - Brush your teeth twice ... locker at school for a quick brushing after lunch. Use a small brush head with ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... DUBLIN , May 26, 2017  Endo International plc ... Campanelli , President and CEO, will represent the Company in ... Global Healthcare Conference on Tuesday, June 13, 2017 at 10:40 ... held at Terranea Resort in Rancho Palos Verdes, ... archive for the event will be available on the Company,s ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
(Date:5/12/2017)... and Canada joint tech company Laughing Face has ... detergent, and features a powerful disinfection process. The company ... washes and sanitizes women,s panties or babies, cloth diapers in 25 ... ... an external water inlet. ...
Breaking Medicine Technology: